Stock Events

ARCA biopharma 

€1.48
0
+€0+0% Friday 07:00

Statistics

Day High
1.48
Day Low
1.48
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
21.67M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.22
-0.17
-0.13
-0.08
Expected EPS
N/A
Actual EPS
-0.08

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HQ10.F. It's not an investment recommendation.

About

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Show more...
CEO
Dr. Michael R. Bristow M.D., Ph.D.
Employees
4
Country
US
ISIN
US00211Y5069
WKN
000A2PGY6

Listings